[Lorlatinib primary hospital patient health management expert consensus (2025 edition)].

Q3 Medicine
{"title":"[Lorlatinib primary hospital patient health management expert consensus (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112152-20250111-00021","DOIUrl":null,"url":null,"abstract":"<p><p>Lorlatinib is a novel third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) used for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) patients. This drug exhibits high affinity, effectively overcoming various resistance mutations, and can penetrate the blood-brain barrier, demonstrating significant efficacy against brain metastases. Lorlatinib exhibits generally manageable safety profiles. To improve patients' adherence and maximize patients survival outcome, physicians need pay attention to lorlatinib related adverse events such as hyperlipidemia, edema, and hypertension, necessitating dose adjustments and symptom management based on individual patient conditions. The Beijing Cancer Prevention and Treatment Research Association has organized relevant experts to formulate the \"Lorlatinib primary hospital patient health management expert consensus (2025 edition)\". This expert consensus provides standardized guidance on the use of lorlatinib for primary hospitals, including pharmacological characteristics, indications, dosage, high-level evidence-based medical research, adverse event management strategy and individualized treatment options. The consensus emphasizes the periodically monitor, identification, assessment, and management of adverse reactions, as well as the importance of long-term follow-up, aiming to maximize the clinical benefits of lorlatinib, ensure the therapeutic effectiveness, improve patients' quality of life and achieve long-term survival.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 ","pages":"1-13"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肿瘤杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112152-20250111-00021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Lorlatinib is a novel third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) used for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) patients. This drug exhibits high affinity, effectively overcoming various resistance mutations, and can penetrate the blood-brain barrier, demonstrating significant efficacy against brain metastases. Lorlatinib exhibits generally manageable safety profiles. To improve patients' adherence and maximize patients survival outcome, physicians need pay attention to lorlatinib related adverse events such as hyperlipidemia, edema, and hypertension, necessitating dose adjustments and symptom management based on individual patient conditions. The Beijing Cancer Prevention and Treatment Research Association has organized relevant experts to formulate the "Lorlatinib primary hospital patient health management expert consensus (2025 edition)". This expert consensus provides standardized guidance on the use of lorlatinib for primary hospitals, including pharmacological characteristics, indications, dosage, high-level evidence-based medical research, adverse event management strategy and individualized treatment options. The consensus emphasizes the periodically monitor, identification, assessment, and management of adverse reactions, as well as the importance of long-term follow-up, aiming to maximize the clinical benefits of lorlatinib, ensure the therapeutic effectiveness, improve patients' quality of life and achieve long-term survival.

[洛拉替尼基层医院患者健康管理专家共识(2025年版)]。
Lorlatinib是一种新型的第三代间变性淋巴瘤激酶(ALK)酪氨酸激酶抑制剂(TKI),用于治疗ALK阳性非小细胞肺癌(NSCLC)患者。该药物具有高亲和力,能有效克服多种耐药突变,并能穿透血脑屏障,对脑转移瘤有显著疗效。洛拉替尼的安全性总体可控。为了提高患者的依从性和最大限度地提高患者的生存结果,医生需要注意氯拉替尼相关的不良事件,如高脂血症、水肿和高血压,需要根据患者的个体情况调整剂量和症状管理。北京市肿瘤防治研究会组织相关专家制定了《劳拉替尼基层医院患者健康管理专家共识(2025年版)》。这一专家共识为基层医院使用氯拉替尼提供了标准化指导,包括药理学特征、适应症、剂量、高水平循证医学研究、不良事件管理策略和个性化治疗方案。共识强调了不良反应的定期监测、识别、评估和管理,以及长期随访的重要性,旨在最大限度地发挥氯拉替尼的临床效益,保证治疗效果,提高患者的生活质量,实现长期生存。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
中华肿瘤杂志
中华肿瘤杂志 Medicine-Medicine (all)
CiteScore
1.40
自引率
0.00%
发文量
10433
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信